The stock may react positively to the improved quarterly loss and continued clinical progress, but the significantly higher annual R&D burn and lack of revenue remain risks. Traders should focus on the upcoming Phase 2b top-line data in Q3 2026 as the next major catalyst.
Price Chart
Executive Summary
Dogwood Therapeutics reported fourth quarter and full-year 2025 financial results, showing a reduced net loss due to lower general and administrative expenses, driven by non-recurring costs from a 2024 business combination. The company has $6.5 million in cash as of year-end and secured $12.5 million in gross proceeds from a January 2026 financing, extending its runway into Q4 2026. Progress in its Halneuron® Phase 2b trial, including interim data showing separation from placebo, is the key clinical catalyst ahead.
Key Financial Metrics
Key Facts
- Net loss attributable to common stockholders was $3.8M in Q4 2025 vs. $8.2M in Q4 2024, a significant improvement.
- Full-year 2025 net loss was $35.5M vs. $12.9M in 2024, driven by $12M in acquired in-process R&D and higher clinical trial costs.
- Cash and cash equivalents were $6.5M as of December 31, 2025; combined with $11.4M in net proceeds from January 2026 financing, the company expects funding through the Halneuron® Phase 2b data readout in Q3 2026.
- Interim analysis of Halneuron® Phase 2b trial showed separation from placebo in a 97-patient subset; final top-line results expected Q3 2026.
- R&D expenses increased to $21.8M in 2025 from $3.5M in 2024 due to clinical development and licensing of SP16.
Financial Impact
Increased annual R&D spend by $18.3M; reduced G&A by $2.6M year-over-year; net loss widened to $35.5M from $12.9M. Cash runway extended into Q4 2026 with $11.4M net proceeds.
Risk Factors
- High cash burn: R&D spend increased 523% year-over-year, raising concerns about future dilution.
- Clinical trial risk: Final Halneuron® data could fail to confirm interim positive signals.
- No revenue: Company remains pre-revenue with no commercial products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258160 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | SC 13D/A | $1.12 | awaiting T+60 | — | $1.13 (+0.89%) |
Oct 19, 2026 7d ago | 8-K | $1.21 | awaiting T+60 | — | $1.13 (−6.61%) |
Oct 19, 2026 7d ago | Press Release | $1.21 | awaiting T+60 | — | $1.13 (−6.61%) |
Aug 13, 2026 10w ago | 8-K | $1.98 | awaiting T+60 | — | $1.13 (+42.93%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.13 (−33.53%) |
May 14, 2026 23w ago | 8-K | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.13 (−42.93%) |
May 14, 2026 23w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.13 (−42.93%) |
Apr 15, 2026 27w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.13 (−33.92%) |
Mar 18, 2026 31w ago | Press Release | $2.97 $1.57 | ▼ −47.14% | ▼ −58.66% | $1.13 (−61.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers